Intro It is December 2022. You work as a financial analyst for Merck & Co. and are tasked with the due diligence on the proposed acquisition of a biotech startup. You estimated the following cash flows for the startup: Year 2023 2024 2025 2026 2027 Expected free cash flow ($ million) (end of year) 70.5 105.75 137.48 164.97 181.47 After 2027, cash flows are expected to grow by 3% per year. Based on the riskiness of your industry, you think that your weighted average cost of capital is 17%. The biotech firm has 5 million shares and bonds worth $120 million outstanding. Part 1 What is the terminal value, i.e., the present value of all free cash flows from 2028 to infinity expressed in 2027-dollars (in $ million)? 0+ decimals Submit Part 2 What is the total value of the company (in $ million)? 0+ decimals Submit Part 3 What is the value per share of common stock (in $)? Attempt 1/10 for 10 pts. 0+ decimals Attempt 1/10 for 10 pts. Attempt 1/10 for 10 pts